Updated: Feb 14, 2021 08:48 IST
Researchers analyze new drug combination to improve survival in advanced kidney cancer
Massachusetts [US], February 14 (ANI): A new clinical study published in The New England Journal of Medicine today and simultaneously presented during the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium claims that a drug combination of Lenvatinib plus pembrolizumab yields better overall survival than single-agent sunitinib when given as first-line therapy in untreated patients with metastatic kidney cancer.
Read more
हिंदी खबर